AR107078A1 - ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE - Google Patents

ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE

Info

Publication number
AR107078A1
AR107078A1 ARP160103887A ARP160103887A AR107078A1 AR 107078 A1 AR107078 A1 AR 107078A1 AR P160103887 A ARP160103887 A AR P160103887A AR P160103887 A ARP160103887 A AR P160103887A AR 107078 A1 AR107078 A1 AR 107078A1
Authority
AR
Argentina
Prior art keywords
methods
well
antimostatin
antibody
regions
Prior art date
Application number
ARP160103887A
Other languages
Spanish (es)
Inventor
Hori Yuji
Katada Hitoshi
Igawa Tomoyuki
Kuramochi Taichi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR107078A1 publication Critical patent/AR107078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anticuerpos antimiostatina así como métodos para la elaboración y utilización de los mismos. También se proveen ácidos nucleicos que codifican los anticuerpos antimiostatina y células huésped que comprenden los ácidos nucleicos. La divulgación también provee polipéptidos que contienen una región Fc variante así como métodos para la elaboración y uso de los mismos. También se proveen ácidos nucleicos que codifican los polipéptidos y células huésped que comprenden los ácidos nucleicos.Antibiostatin antibodies as well as methods for their preparation and use. Nucleic acids encoding antimiostatin antibodies and host cells comprising nucleic acids are also provided. The disclosure also provides polypeptides containing a variant Fc region as well as methods for making and using them. Nucleic acids encoding polypeptides and host cells comprising nucleic acids are also provided.

ARP160103887A 2015-12-18 2016-12-16 ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE AR107078A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18

Publications (1)

Publication Number Publication Date
AR107078A1 true AR107078A1 (en) 2018-03-21

Family

ID=59011957

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103887A AR107078A1 (en) 2015-12-18 2016-12-16 ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE

Country Status (16)

Country Link
EP (1) EP3390443A4 (en)
JP (4) JP6142069B1 (en)
KR (4) KR20230027321A (en)
CN (2) CN115028721A (en)
AR (1) AR107078A1 (en)
AU (1) AU2016372934B2 (en)
BR (1) BR112018011073A2 (en)
CA (1) CA3002422C (en)
EA (1) EA201891420A1 (en)
HK (1) HK1254755A1 (en)
MX (1) MX2018007145A (en)
MY (1) MY189425A (en)
PH (1) PH12018501280A1 (en)
SG (2) SG10201707267RA (en)
TW (3) TWI605057B (en)
WO (1) WO2017104783A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
RU2510400C9 (en) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Modification method of isoelectric point of antibody by means of amino-acid replacements in cdr
CN102056946A (en) 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102568454B1 (en) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
DK2857420T3 (en) 2012-05-30 2020-11-23 Chugai Pharmaceutical Co Ltd TARGET TISSUE SPECIFIC ANTIGIN BINDING MOLECULE
TW202340236A (en) 2012-08-24 2023-10-16 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
EP3078744B1 (en) 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
TWI779010B (en) 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
MX2017008978A (en) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
TWI611811B (en) * 2016-06-17 2018-01-21 中外製藥股份有限公司 Anti-myostatin antibodies and methods of use
AU2017305073B2 (en) 2016-08-05 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Composition for prevention or treatment of IL-8 related diseases
JP7337698B2 (en) 2017-02-28 2023-09-04 シージェン インコーポレイテッド Cysteine mutated antibodies for conjugation
EA202190451A1 (en) 2018-08-10 2021-07-13 Чугаи Сейяку Кабусики Кайся ANTI-CD137 ANTIGEN-BINDING MOLECULES AND THEIR APPLICATION
WO2020209318A1 (en) * 2019-04-10 2020-10-15 中外製薬株式会社 Method for purifying fc region-modified antibody
AU2020346632A1 (en) * 2019-09-13 2022-05-05 Provincial Health Services Authority Anti-oncolytic virus antigen antibodies and methods of using same
RU2750267C1 (en) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Recombinant growth differentiation factor 11 (gdf11), a method for its production, an injectable drug for increasing the muscle mass of mammals and poultry as well as a method of using the drug
TW202144395A (en) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 Anti-CD137 antigen-binding molecule for use in cancer treatment
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
WO2023213779A1 (en) 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (en) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 Analysis method for rapidly determining anti-CD40 monoclonal antibody based on Gyrolab platform

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
CN101103045B (en) * 2004-09-24 2015-11-25 安姆根有限公司 The Fc molecule modified
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2007292555B2 (en) * 2006-09-05 2012-05-31 Eli Lilly And Company Anti-myostatin antibodies
PE20091163A1 (en) * 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
CN102056946A (en) * 2008-04-11 2011-05-11 中外制药株式会社 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TW201029662A (en) * 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
BR112012022917A2 (en) * 2010-03-11 2017-01-10 Pfizer ph-dependent antigen binding antibodies
AR081556A1 (en) * 2010-06-03 2012-10-03 Glaxo Group Ltd HUMANIZED ANTIGEN UNION PROTEINS
SI2883449T1 (en) * 2012-03-16 2018-05-31 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI619729B (en) * 2012-04-02 2018-04-01 再生元醫藥公司 Anti-hla-b*27 antibodies and uses thereof
EA028244B1 (en) * 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS
TW202340236A (en) * 2012-08-24 2023-10-16 日商中外製藥股份有限公司 Fcγriib-specific fc region variant
SG10201800800YA (en) * 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
TN2016000057A1 (en) * 2013-08-14 2017-07-05 Novartis Ag Methods of treating sporadic inclusion body myositis
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
AU2015342936B2 (en) * 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
TWI779010B (en) * 2014-12-19 2022-10-01 日商中外製藥股份有限公司 ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE
WO2017104783A1 (en) * 2015-12-18 2017-06-22 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Also Published As

Publication number Publication date
CN115028721A (en) 2022-09-09
KR102501335B1 (en) 2023-02-17
KR20230027321A (en) 2023-02-27
CN108473562A (en) 2018-08-31
EP3390443A1 (en) 2018-10-24
KR101820637B1 (en) 2018-01-19
TW201726718A (en) 2017-08-01
KR20240058997A (en) 2024-05-03
HK1254755A1 (en) 2019-07-26
RU2018125431A3 (en) 2020-07-06
JP2017112997A (en) 2017-06-29
WO2017104783A1 (en) 2017-06-22
AU2016372934B2 (en) 2023-10-05
RU2018125431A (en) 2020-01-20
KR20180085711A (en) 2018-07-27
JP7053164B2 (en) 2022-04-12
MX2018007145A (en) 2018-08-15
MY189425A (en) 2022-02-10
JP2017148069A (en) 2017-08-31
SG10201707267RA (en) 2017-10-30
EP3390443A4 (en) 2019-11-13
JP6142069B1 (en) 2017-06-07
TWI749057B (en) 2021-12-11
TWI605057B (en) 2017-11-11
AU2016372934A1 (en) 2018-05-10
KR20170085028A (en) 2017-07-21
CA3002422A1 (en) 2017-06-22
PH12018501280A1 (en) 2019-01-28
CN108473562B (en) 2022-06-17
TW201808992A (en) 2018-03-16
TW202231662A (en) 2022-08-16
EA201891420A1 (en) 2019-02-28
JP2022097485A (en) 2022-06-30
SG11201610812WA (en) 2017-07-28
JP2024023427A (en) 2024-02-21
CA3002422C (en) 2024-04-16
BR112018011073A2 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
AR107078A1 (en) ANTIMOSTATIN ANTIBODY, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS AS WELL AS METHODS OF USE
CL2017001584A1 (en) Antibiostatin antibodies, polypeptides containing variant fc regions, and methods of use
ECSP19026178A (en) ANTI-PD-1 ANTIBODIES AND THEIR USES
EA201990017A1 (en) ANTIBODIES TO MYOSTATIN AND WAYS OF THEIR APPLICATION
CO2018002450A2 (en) Gitrl fusion proteins and uses thereof
CL2019000261A1 (en) Modified polypeptides and uses thereof.
CY1121934T1 (en) ANTI-FCRN ANTIBODIES
PE20210107A1 (en) ANTI-CD3 ANTIBODIES AND METHODS OF USE
PE20190563A1 (en) OPTIMIZED MINI-DISTROPHIN GENES AND EXPRESSION CASSETS AND THEIR USE
UY37523A (en) ANTI-OX40 ANTIBODIES AND ITS USES
AR105634A1 (en) ANTIBODIES THAT JOIN IL 8 AND ITS USES
PE20180672A1 (en) ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE OF THE SAME
CL2015002654A1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
BR112019012343A2 (en) il-11ra antibodies
AR104604A1 (en) ANTI-FcRn ANTIBODIES
AR101845A1 (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
PE20150646A1 (en) METHODS OF TREATING A TAUOPATHY
CY1122214T1 (en) ANTIBODIES SPECIFIC TO TON FCRN
DOP2016000220A (en) TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND USE OF THESE.
BR112016021739A2 (en) METHOD FOR PREPARING A POLOXAMER FOR USE IN A CELL CULTURE MEDIA
CR20150477A (en) IL-22 POLYPEPTIDES AND IL-22 FC FUSION PROTEINS AND METHODS OF USE